Abstract
Merrimack Pharmaceuticals is narrowing its focus to several systems-biology-derived oncology drug candidates and its approved pancreatic cancer drug Onivyde, a liposomal formulation of irinotecan. It intends to eliminate more than $200 million in expenses over the next two years. The company has initiated an immediate 22% reduction in its staff, which was 426 employees as of January. Merrimack’s CEO, Robert Mulroy, also has resigned.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
